15:03:37 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Newbury Pharmaceuticals är verksamma inom läkemedelsbranschen. Bolaget utvecklar en pipeline av egenutvecklade och licensierade produkter med fokus på specialläkemedel inom områden som onkologi, sällsynta sjukdomar och neurologi. Bolaget är verksamma inom den skandinaviska marknaden. Newbury Pharmaceuticals har sitt huvudkontor i Lund.

Kalender

2023-01-11 Årsstämma 2023
2023-01-11 Kvartalsrapport 2023-Q1
2022-10-13 Bokslutskommuniké 2022
2022-07-06 Kvartalsrapport 2022-Q3
2022-04-13 Kvartalsrapport 2022-Q2
2022-08-02 14:30:00

Newbury Pharmaceuticals is pleased to announce the appointment of Mrs. Andrea Karnitschky as Senior Director and Head of Business Development. From August 1st 2022, Andrea Karnitschky’s responsibilities include the expansion of the pipeline and the development of strategic partnerships.

We are very pleased to strengthen our team with Andrea who has an impressive track record in deal making. Andrea will be an important addition to Newbury, and I look forward to the collaboration to further grow our strong pipeline with new products and new exciting business opportunities”, says Lars Minor, CEO, Newbury Pharmaceuticals.

Prior to joining Newbury, Andrea Karnitschky held a position as Director & Head of In-licensing Europe at Dr. Reddy´s Laboratories SA following an appointment as Head of Sourcing at betapharm Arzneimittel GmbH. Andrea Karnitschky has a broad and deep network within the global pharmaceutical industry.

“I am excited to join Newbury – a young, dynamic, entrepreneurial company with high ambitions. It will be an interesting challenge to contribute to the growth of Newbury.” says Andrea Karnitschky.